Skip to main content
main-content

Neuer Inhalt Free Registration

Gain full access to the latest clinical content available from Springer Nature

Editors' pick

17-10-2017 | Semaglutide (investigational) | News

Promising phase II results for oral semaglutide

Phase II findings show that daily oral semaglutide provides glycemic control that is significantly better than that of placebo and, at the highest doses, is similar to that achieved with weekly injectable semaglutide.

17-10-2017 | Glucagon-like peptide-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

04-10-2017 | Type 1 diabetes | Case study | Article

Atypical diabetes: Case 1

In this first entry to our series on atypical forms of diabetes, Editorial Board member Jay Shubrook highlights an easy-to-miss form of the disease and challenges you to make the correct diagnosis.

Latest from across the site

19-10-2017 | Vildagliptin | News

News in brief

Unclear impact of vildagliptin treatment in patients with HF and type 2 diabetes

Results of the VIVIDD trial indicate that it is unclear whether treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin has a beneficial effect on cardiac outcomes among patients with heart failure and type 2 diabetes.

18-10-2017 | Heart failure | News

Glycemic control, drug treatment linked to outcome in patients with HF and type 2 diabetes

Results of a study published in JACC: Heart Failure suggest that glycemic control and drug treatment have complex associations with adverse outcomes among patients with heart failure and type 2 diabetes.

Source:

JACC Heart Fail 2017; Advance online publication

17-10-2017 | Semaglutide (investigational) | News

Promising phase II results for oral semaglutide

Phase II findings show that daily oral semaglutide provides glycemic control that is significantly better than that of placebo and, at the highest doses, is similar to that achieved with weekly injectable semaglutide.

Source:

JAMA 2017; 318: 1460–1470

17-10-2017 | Glucagon-like peptide-1 agonists | At a glance | Article

Round up of the GLP-1 receptor agonist CV outcome trials

medwireNews provides a brief overview of the published and ongoing glucagon-like peptide-1 receptor agonist cardiovascular outcomes trials.

17-10-2017 | Prediabetes | News

Teaming up with commercial weight management providers aids type 2 diabetes prevention

A partnership between primary care and commercial weight management providers could help reduce the risk for type 2 diabetes among patients with hyperglycemia, UK study findings show.

Source:

BMJ Open Diab Res Care 2017; 5: e000418

17-10-2017 | Glucagon-like peptide-1 agonists | Feature | Article

GLP-1 receptor agonists: Cardiovascular trials and triumphs

With four GLP-1 receptor agonists now having published cardiovascular outcome data, medwireNews takes a look at how the experts are interpreting the conflicting findings, and what they mean for prescribing decisions.

Meet our UK Advisory Board

New Content Item Meet our international Advisory Board

image credits